Is Syncom Formul. overvalued or undervalued?

As of 29 September 2025, the valuation grade for Syncom Formul. has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE Ratio of 26.64, an EV to EBITDA of 23.93, and a PEG Ratio of 0.26, which suggests that while the company has potential growth, its current price does not reflect its underlying value adequately.
In comparison to its peers, Syncom Formul.'s PE Ratio is lower than Sun Pharma's 33.27 and significantly lower than Divi's Lab's 65.91, both of which are categorized as expensive or very expensive. However, it is higher than Cipla's attractive PE of 22.3 and Dr. Reddy's Labs' attractive PE of 18.15. The recent performance of Syncom Formul. has been underwhelming, with a year-to-date return of -18.50%, contrasting sharply with the Sensex's positive return of 2.85% during the same period, reinforcing the view that the stock is overvalued.